Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18358944 | 0.84 | MMP2 (0.59) | KMT2AMMP2MMP9ALDH1A1SMN1; SMN2 | |
| SCHEMBL3146514 | 0.82 | SMN1; SMN2 (0.48) | KMT2AL3MBTL1MMP2MMP9NPC1 | |
| SCHEMBL24279578 | 0.81 | LMNA (0.54) | KMT2AL3MBTL1MMP2MMP9POLB | |
| SCHEMBL5782282 | 0.80 | ALDH1A1 (0.49) | KMT2AL3MBTL1ALDH1A1LMNAMEN1 | |
| SCHEMBL3157147 | 0.80 | MEN1 (0.57) | KMT2AL3MBTL1MMP2MMP9ALDH1A1 | |
| SCHEMBL3157137 | 0.79 | ALDH1A1 (0.58) | KMT2AL3MBTL1MMP2MMP9NPC1 | |
| SCHEMBL6318614 | 0.76 | ALDH1A1 (0.48) | KMT2AL3MBTL1MMP2MMP9NPC1 | |
| SCHEMBL21932071 | 0.76 | MMP2 (0.41) | KMT2AL3MBTL1MMP2MMP9NPC1 | |
| SCHEMBL25894216 | 0.76 | ALDH1A1 (0.60) | KMT2AL3MBTL1NPC1POLBALDH1A1 | |
| SCHEMBL13645024 | 0.73 | ALDH1A1 (0.47) | KMT2AL3MBTL1NPC1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | KMT2A 3530/4885L3MBTL1 4639/4885MMP2 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.